Burning Rock Biotech
- Company typePublic
- Founded2015
- HeadquartersGuangzhou, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Burning Rock Biotech firmographics
Firmographics- Name
- Burning Rock Biotech
- Legal name
- Burning Rock Biotech Limited
- Website
- https://brbiotech.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Burning Rock Biotech industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Burning Rock Biotech is headquartered
LocationHeadquarters
- HQ city
- Guangzhou
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Burning Rock Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Central Laboratory Testing Services: NGS-based cancer testing services performed at Burning Rock's central laboratories (Guangzhou and Irvine) for cancer patients, providing therapy selection and molecular profiling results to guide treatment decisions.
- In-Hospital Testing Business: Sale of NGS testing kits and support services to hospitals that have established in-house NGS testing platforms. Revenue generated from kit sales, technical support, and ongoing services. Growing revenue share from 43% in Q1 2025 to 49% in Q1 2026, representing RMB52.8 million (US$7.6 million) in Q1 2026.
- Pharma Research and Development Services: Comprehensive biomarker detection and companion diagnostics development services for pharmaceutical companies, including genomic data solutions, clinical trial solutions, precision patient recruitment, and CDx development and commercialization. Revenue was RMB22.8 million in Q1 2026, with 34.5% growth in 2025. The company partners with over 150 pharmaceutical enterprises globally.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Burning Rock Biotech product offering
Product offeringCore offering
Burning Rock Biotech develops and sells NGS-based diagnostic kits (tissue and liquid biopsy panels) and provides central laboratory cancer genomic testing services, multi-cancer early detection blood tests, and MRD monitoring products. It also delivers companion diagnostics development and biomarker services to pharmaceutical companies, supported by CLIA/CAP-accredited labs in China and the US.
Product overview
Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company offering an integrated portfolio of NGS-based diagnostic products and services. The core product lines include tissue-based testing products (OncoScreen Plus, OncoScreen Focus) and liquid biopsy solutions (OncoCompass Plus, OncoCompass Target), all available as CE-IVDD marked or NMPA-approved kits. The OncoScreen Focus CDx serves as the companion diagnostic variant for targeted therapies. For early cancer detection, the company offers the OverC multi-cancer detection blood test based on ELSA-seq technology, which holds both CE marking and FDA/NMPA Breakthrough Device Designation. Supporting platforms include the MAGNIS BR automated library preparation system and OncoMaster data analysis system. The company also provides comprehensive pharma services including biomarker detection and CDx development through its globally accredited laboratory network. These products and services work together to cover the full precision oncology cycle from early detection and therapy selection to recurrence monitoring, supported by in-house developed technologies including ELSA-seq methylation profiling, HS-UMI ultra-deep sequencing, and tumor-informed MRD detection (CanCatch).
Differentiator
Problem solved
Functional benefit
Brands
- OncoScreen: NGS-based cancer mutation profiling tissue kits for solid tumor testing
- OncoCompass
- OverC
- CanCatch
- OncoMaster
- ELSA-seq
- OncoGuide
- MAGNIS BR
Products and services
- OncoCompass Plus (Liquid Biopsy)
Quantifiable outcome
- Stage-shifting potential of 38.7%-46.4% of patients through annual OverC testing, improving five-year survival rate for 33.1%-40.4% of patients.
- +4 more outcomes
Companies that use Burning Rock Biotech
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Burning Rock Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability8 records
Feature5 records
Burning Rock Biotech partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major and core.
- Fudan University Shanghai Cancer CentermajorJoint study with team led by Professor Haiquan Chen, Professor Hong Hu, and Professor Yang Zhang from Fudan University Shanghai Cancer Center, published in Journal for ImmunoTherapy of Cancer (IF=10.6). Study validated ctDNA-MRD potential for evaluating perioperative treatment response in squamous cell lung cancer.
- D3 BiomajorPartnership for ctDNA testing services supporting clinical studies on Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. CanCatch provided high-sensitivity ctDNA testing services for NSCLC studies presented at 2026 AACR, including one selected for plenary oral session.
- Riken GenesiscorePartnership with Riken Genesis for commercialization of OncoGuide™ OncoScreen™ Plus CDx System in Japan. The CDx system received Manufacturing and Marketing Approval from Japan's MHLW as companion diagnostic for AstraZeneca's capivasertib (Truqap) in breast cancer. Riken Genesis handles distribution, insurance coverage, and market access in Japan.
- Dizal PharmaceuticalcoreJoint development and co-commercialization of companion diagnostics for EGFR exon20ins mutation detection supporting sunvozertinib targeted therapy for NSCLC. This represents the first co-developed NGS-based CDx for lung cancer approved by NMPA following CDx guideline release in China.
- BayermajorCollaboration to increase patient access to precision cancer medicines through companion diagnostics development and commercialization.
- Boehringer IngelheimcoreMaster Service Agreement for oncology companion diagnostics development, focusing on clinical trials for MDM2-p53 antagonist brigimadlin (BI 907828) and CDx product development in China. The partnership aims to provide precise treatment options for patients with MDM2-amplified, TP53 wild-type cancers including biliary tract carcinoma.
- Merck KGaA (Germany)majorCollaboration on liquid biopsy-based CDx development using Burning Rock's OncoCompass Target platform, supporting Merck's oncology drug development programs.
- IMPACT TherapeuticscoreGlobal strategic partnership for companion diagnostics development for Senaparib (PARP inhibitor) targeting prostate cancer. Includes CDx submissions to both FDA and NMPA, supported by Burning Rock's CLIA and CAP accredited labs.
- National Cancer Center / Cancer Hospital of Chinese Academy of Medical SciencesmajorLaunch of PRESCIENT study, the first blood-based, pan-cancer early-detection study in China using multi-omics approach. Expected to enroll 11,879 participants across 22 cancer types. Led by Professor Jie He and Professor Jie Wang from National Cancer Center.
- Abbisko TherapeuticsmajorStrategic partnership for CDx assay development for ABSK091 (FGFR inhibitor) to detect FGFR genetic alterations in patients with urothelial carcinoma. Abbisko has exclusive global rights for development, manufacture, and commercialization.
- CStone PharmaceuticalsmajorStrategic partnership for co-development and commercialization of companion diagnostics for pralsetinib (Blueprint Medicines) for detection of RET alterations in cancer patients in China.
- IlluminacoreStrategic cooperation to promote development and standardization of NGS-based cancer therapy selection in China based on NextSeq 550Dx system. First genetic testing company in China to achieve development of IVD tests for both ctDNA and tissue based on NextSeq 550Dx system.
- Shanghai Zhongshan HospitalmajorCollaboration on PREDICT (Pan-CanceR Early DetectIon ProjecT) study, the first early detection study in multiple cancer types in China. 14,000 patient enrollment expected. Led by Professor Jia Fan, Fellow of Chinese Academy of Sciences and President of Shanghai Zhongshan Hospital.
- CTONG (Chinese Thoracic Oncology Group)majorCo-founded NGS Clinical Research Lab at Guangzhou International Bio Island for non-profit clinical studies. 3,000m2 facility with 19 independent labs covering sample processing, nucleic acid extraction, library construction, sequencing, and data analysis. CTONG's first partner for founding NGS lab.
- AstraZeneca ChinamajorDesignated as AstraZeneca's sole strategic NGS lung cancer testing partner. Participated in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD). Also launched China's first NGS charitable project for ovarian cancer - 'Love Me, Test Me' BRCA testing project.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Burning Rock Biotech competitors and assessment
Company assessmentBroad incumbents
- NeoGenomics: US-listed oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE, RaDaR MRD). Comparable in oncology-focused lab services, NGS profiling, and pharma/biopharma clinical trial support.
- Foundation Medicine (Roche): Roche-owned leader in NGS-based comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head with Burning Rock's OncoScreen Plus and OncoCompass products in CDx and tissue profiling, with broader pharma services scale.
- Exact Sciences: US-listed molecular diagnostics company with Cologuard (CRC screening), Oncotype DX, and emerging liquid biopsy products. Comparable in cancer molecular diagnostics for therapy selection and screening, though broader and larger-scale than Burning Rock.
Direct peers
- Caris Life Sciences: US-based molecular profiling company offering MI Profile tumor/NGS profiling and Caris Assure liquid biopsy MRD tests. Directly comparable to Burning Rock's tissue and blood-based NGS oncology products targeting therapy selection and recurrence monitoring.
- Natera: US-listed molecular diagnostics company with Signatera tumor-informed MRD test and oncology NGS products. Direct comparable in liquid biopsy MRD detection (vs. Burning Rock's CanCatch) and oncology therapy selection testing.
- Guardant Health: US-listed liquid biopsy and NGS oncology diagnostics company offering ctDNA-based therapy selection and MRD tests (Guardant360, Reveal). Directly comparable to Burning Rock's OncoCompass liquid biopsy franchise in product category, customer base (oncologists/hospitals), and business model.
- Personalis: US-listed NGS-based oncology testing company offering NeXT Personal MRD test and ImmunoID Next tumor profiling. Comparable in tumor-informed liquid biopsy MRD and comprehensive NGS oncology panels for pharma and clinical customers.
- Tempus AI: US-listed precision medicine company offering NGS-based oncology profiling (Tempus xT, xR), AI-enabled clinical decision support, and biopharma data services. Comparable in NGS oncology testing, pharma CDx/biomarker services, and AI/bioinformatics platform offerings.
- Geneseeq Technology: China-based NGS oncology diagnostics competitor offering Gene+Seq tumor profiling, liquid biopsy, and pharma CDx services. Closest China-domestic direct peer to Burning Rock in NGS oncology testing market, technology, and pharma partnership model.
Emerging players
- Predicine: US/China-based liquid biopsy and NGS diagnostics company offering cell-free DNA/RNA assays and MRD detection for pharma and clinical customers. Comparable in liquid biopsy ctDNA technology, MRD focus, and dual US-China operational footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Burning Rock Biotech social profiles
Digital presenceBurning Rock Biotech compliance and trust
Trust signalCompliance11 records
Burning Rock Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Burning Rock Biotech leadership team
Management profileNumber of profiles
Profiles3 records
Burning Rock Biotech subsidiaries and ownership
Company hierarchySubsidiaries10 records
Burning Rock Biotech funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Burning Rock Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Burning Rock Biotech
What does Burning Rock Biotech do?
Burning Rock Biotech develops and sells NGS-based diagnostic kits (tissue and liquid biopsy panels) and provides central laboratory cancer genomic testing services, multi-cancer early detection blood tests, and MRD monitoring products. It also delivers companion diagnostics development and biomarker services to pharmaceutical companies, supported by CLIA/CAP-accredited labs in China and the US.
Is Burning Rock Biotech a public or private company?
Burning Rock Biotech is a public company. It is classified as public and is currently operating.
When was Burning Rock Biotech founded?
Burning Rock Biotech was founded in 2015. It employs 1,001 to 5,000 people.
Where is Burning Rock Biotech based?
Burning Rock Biotech is headquartered in Guangzhou, China, in the Asia region.
How does Burning Rock Biotech make money?
Three revenue lines are on record. Central Laboratory Testing Services are the primary driver. The others are in-Hospital Testing Business and pharma Research and Development Services.
Who are Burning Rock Biotech's main competitors?
Broad incumbents on record are NeoGenomics, Foundation Medicine (Roche) and Exact Sciences. Direct peers are Caris Life Sciences, Natera, Guardant Health, Personalis, Tempus AI and Geneseeq Technology. Predicine is listed as an emerging player.
Does Burning Rock Biotech have an API?
No public API is recorded for Burning Rock Biotech.
What industry is Burning Rock Biotech in?
Burning Rock Biotech's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.